Zentek Ltd. - ZTEK STOCK NEWS

Welcome to our dedicated page for Zentek Ltd. news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek Ltd. stock.

Zentek Ltd. (Nasdaq: ZTEK, TSX-V: ZEN) is an intellectual property development and commercialization company focusing on next-generation healthcare solutions for prevention, detection, and treatment. Zentek is at the forefront of commercializing ZENGuard, a groundbreaking coating with 99% antimicrobial effectiveness, including activity against COVID-19. This technology has applications in a variety of fields, including surgical masks and HVAC systems.

The company operates a state-of-the-art production facility in Guelph, Ontario, and is ISO 13485:2016 certified. Zentek has developed a synergistic relationship with McMaster University to leverage an exclusive global license for their aptamer-based rapid pathogen detection technology. This partnership has led to promising results, including the C19HBA aptamer, which has shown therapeutic potential against SARS-CoV-2, outperforming leading monoclonal antibodies in preclinical trials.

Through its wholly-owned subsidiary Triera Biosciences Ltd., Zentek continues to advance its aptamer technology. Notably, their C19HBA aptamer has demonstrated robust preclinical efficacy in both prophylactic and therapeutic settings against various SARS-CoV-2 variants, including Omicron XBB 1.5. The company is now moving towards Phase 1 clinical trials and exploring further applications for their platform in infectious diseases and oncology.

In addition to healthcare, Zentek has made significant strides in the HVAC industry. The company's ZenGUARD™ Enhanced Air Filters aim to improve air quality without increasing energy consumption or emissions. Zentek's commitment to innovation is further evidenced by a series of partnerships and distribution agreements, including collaborations with Medwell Solutions LLC and DCL Supply Ltd. These partnerships aim to expand the market reach of Zentek's antimicrobial technologies.

Recent Achievements:

• Significant progress in preclinical trials for C19HBA aptamer as a therapeutic for SARS-CoV-2.
• A promising safety and toxicity profile for the C19HBA aptamer in preclinical tests.
• Exclusive distribution agreements for ZenGUARD™ Enhanced Surgical Masks in the U.S. with Medwell Solutions LLC and DCL Supply Ltd.
• Launch preparations for ZenGUARD™ Enhanced Air Filters in the HVAC market.
• Second patent for their GO-Ag+ nanocomposite as an antimicrobial agent, expanding its potential applications to both human and veterinary medicine.

Zentek continues to focus on commercializing its proprietary technologies, aiming to provide significant health benefits while also addressing environmental concerns. By offering innovative, safer, and greener products, Zentek seeks to give its commercial partners a competitive edge in their respective markets.